Neoantigens are newly formed antigens that have not been previously recognized by the immune system. It is a key element of cancer immunotherapies. NovoNeoantigen™ 2.0 is a robust and comprehensive bioinformatics analysis service developed by Novogene for discovering tumor-specific neoantigens using whole exome sequencing (WES) and mRNA sequencing (mRNA-Seq) data from paired tumor-normal samples.
NovoNeoantigenTM 2.0 Service Overview
Data Quality Guarantee
Recommended Sequencing Depth
NovoNeoantigen™ 2.0 Bioinformatics Analysis Workflow
Predicts all types of HLA-I and six types of HLA-II (including DQA1, DQB1, DPA1, DPB1, DRB1 and DRB5) with WES data from the DNA of normal tissue samples.
Identifies somatic mutations (SNV, InDel and Fusion) and their gene expression level with WES and mRNA-Seq data. It also generates other important results including TMB and SNV Phasing.
Predicts tumor-specific neoantigens based on the analysis above and antigen affinity analysis.
NovoNeoantigen™ 2.0 was applied to the HLA typing of 10 samples involving 100 HLA alleles from the 1,000 Genomes database. The overall coincidence rate was 91%.
To evaluate the performance of the pipeline in predicting immunogenic neoantigens, we assembled 9 known and experimentally-validated immunogenic neoantigens from the literature[1, 2, 3].
We spiked in these neoepitopes into a BAM file. The results showed that NovoNeoantigen™ 2.0 is able to accurately identify 8 immunogenic peptides, including 5 HLA-I binding peptides and 3 HLA-II binding peptides.
For Research Use Only. The content provided herein may relate to products that have not been approved by the regulatory authorities of where this document is circulated. The clinical application of such products should thus be limited to research only. The content of this document is subject to change without notice. © 2019 Novogene Co., Ltd. All rights reserved. All trademarks are the property of Novogene Co., Ltd. and its subsidiaries unless otherwise specified.”